Heparanase induces VEGF C and facilitates tumor lymphangiogenesis.
Heparanase is an endoglycosidase that specifically cleaves heparan sulfate side chains, a class of glycosaminoglycans abundantly present in the extracellular matrix and on the cell surface. Heparanase activity is strongly implicated in tumor angiogenesis and metastasis attributed to remodeling of the subepithelial and subendothelial basement membranes. We hypothesized that similar to its proangiogenic capacity, heparanase is also engaged in lymphangiogenesis and utilized the D2-40 monoclonal antibody to study lymphangiogenesis in tumor specimens obtained from 65 head and neck carcinoma patients. Lymphatic density was analyzed for association with clinical parameters and heparanase staining. We provide evidence that lymphatic vessel density (LVD) correlates with head and neck lymph node metastasis (N-stage, p = 0.007) and inversely correlates with tumor cell differentiation (p = 0.007). Notably, heparanase staining correlated with LVD (p = 0.04) and, moreover, with VEGF C levels (p = 0.01). We further demonstrate that heparanase overexpression by epidermoid, breast, melanoma and prostate carcinoma cells induces a 3- to 5-fold elevation in VEGF C expression in vitro and facilitates tumor xenograft lymphangiogenesis in vivo, whereas heparanase gene silencing was associated with decreased VEGF C levels. These findings suggest that heparanase plays a unique dual role in tumor metastasis, facilitating tumor cell invasiveness and inducing VEGF C expression, thereby increasing the density of lymphatic vessels that mobilize metastatic cells.
Cohen-Kaplan
Victoria
V
Cancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Naroditsky
Inna
I
Zetser
Anna
A
Ilan
Neta
N
Vlodavsky
Israel
I
Doweck
Ilana
I
D000368:Aged; D000818:Animals; D045744:Cell Line, Tumor; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005966:Glucuronidase / Q000235:genetics / Q000378:metabolism*; D006258:Head and Neck Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D042583:Lymphangiogenesis; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009367:Neoplasm Staging; D015996:Survival Rate; D042582:Vascular Endothelial Growth Factor C / Q000235:genetics / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays; D000099175:Heparanase
D005966:Glucuronidase; D042582:Vascular Endothelial Growth Factor C; D000099175:Heparanase
J Clin Invest. 2004 Apr;113(7):1040-50
15057311
Semin Thromb Hemost. 2007 Jul;33(5):557-68
17629854
Pathophysiol Haemost Thromb. 2006;35(1-2):116-27
16855356
Lab Invest. 2003 May;83(5):613-22
12746471
Am J Pathol. 1988 Feb;130(2):393-400
3277442
Clin Cancer Res. 2005 Nov 15;11(22):7995-8005
16299228
Nat Med. 2001 Feb;7(2):192-8
11175850
Cancer Cell. 2002 Apr;1(3):219-27
12086857
Biochem Biophys Res Commun. 2005 May 27;331(1):175-80
15845375
Cancer Res. 2003 Dec 15;63(24):8749-56
14695190
Int J Cancer. 2001 Sep 20;95(5):295-301
11494228
Cancer Res. 1983 Jun;43(6):2704-11
6601984
Nat Med. 1999 Jul;5(7):793-802
10395325
Lab Invest. 2004 Oct;84(10):1289-304
15286661
J Cell Mol Med. 2007 May-Jun;11(3):427-52
17635638
Neoplasia. 2006 Dec;8(12):1055-61
17217623
Science. 1983 May 6;220(4597):611-3
6220468
J Thromb Haemost. 2006 Nov;4(11):2443-51
16970801
Cancer Res. 2003 Apr 15;63(8):1920-6
12702584
FASEB J. 2005 Feb;19(2):211-21
15677344
Cell Tissue Res. 2003 Oct;314(1):167-77
12883995
Int J Cancer. 2006 Oct 15;119(8):1755-60
16557570
J Natl Cancer Inst. 2004 Aug 18;96(16):1219-30
15316057
Am J Pathol. 2005 Mar;166(3):913-21
15743802
Ann Oncol. 2003 Oct;14(10):1505-10
14504050
Chem Biol. 2005 Mar;12(3):267-77
15797210
Cancer. 2001 Aug 1;92(3):556-68
11505400
Cancer Res. 2002 Mar 1;62(5):1315-20
11888898
Gynecol Obstet Invest. 2003;56(2):77-82
12904690
Cancer Res. 2003 Nov 15;63(22):7733-41
14633698
Int J Cancer. 2006 Apr 1;118(7):1609-17
16217746
Clin Cancer Res. 2001 May;7(5):1299-305
11350898
Head Neck. 2001 Feb;23(2):147-59
11303632
Curr Pharm Des. 2007;13(20):2057-73
17627539
J Cell Sci. 2004 May 1;117(Pt 11):2249-58
15126626
Cancer Res. 2006 Feb 1;66(3):1455-63
16452201
J Surg Oncol. 2004 Sep 15;87(4):174-81
15334632
Int J Biochem Cell Biol. 2006;38(12):2018-39
16901744
Clin Cancer Res. 2001 Mar;7(3):462-8
11297234
Differentiation. 2006 Jun;74(5):235-43
16759289
Gynecol Oncol. 2007 Oct;107(1):45-51
17604828
Cancer Res. 2003 Dec 15;63(24):8821-6
14695198
Breast Cancer Res Treat. 2007 Jul;104(1):13-9
17004106
Cancer. 2004 Sep 1;101(5):973-8
15329906
J Pathol. 2005 Jun;206(2):170-7
15846845
Mini Rev Med Chem. 2004 Aug;4(6):693-702
15279603
Clin Cancer Res. 2006 Dec 1;12(23):6865-8
17145802
FASEB J. 2001 Jul;15(9):1661-3
11427519
Br J Pharmacol. 2007 May;151(1):1-14
17339837
Biochem Biophys Res Commun. 2003 Sep 5;308(4):885-91
12927802
Biochemistry. 1989 Feb 21;28(4):1737-43
2541764
Blood. 2006 May 1;107(9):3609-16
16384929
Curr Med Chem. 2006;13(18):2101-11
16918340